The FDA has approved Novartis’ Fabhalta (iptacopan) as the first and only treatment for C3 glomerulopathy (C3G). Previously, patients with C3G were forced to rely on supportive care and broad ...

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...

The Department of Pediatrics of AIIMS Bhopal organized various awareness programs from March 11 to March 17 as part of World Kidney Week. The event featured cultural activities such as painting, dance ...

Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...

Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis ... immunogenicity, hemolytic activity and toxicity. The utility of ...

Transient microscopic or macroscopic hematuria can appear after vigorous exercise, but exercise-induced hematuria should be a diagnosis of ... may indicate hemolysis or hepatocellular disease.

Increased testing for Rh and Kell phenotypes could reduce the risk of adverse transfusion reactions and HDFN, a study found.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, potentially life-threatening disorder. It causes the red blood cells to break apart, a process called hemolysis. This releases hemoglobin from ...

A 65-year-old male presented for his annual exam. The medical assistant (MA) checking the patient in remarked that he is ...

DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a complement inhibitor indicated to treat adult patients with PNH. The report ...